Evidence map›Paper›PMID 23773964›Full record

ArticleThe Journal of arthroplasty2014

Early experience with the Vanguard complete total knee system: 2-7 years of follow-up and risk factors for revision.

Arthur J Kievit, Matthias U Schafroth, Leendert Blankevoort, Inger N Sierevelt, C Niek van Dijk, Rutger C I van Geenen

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The Journal of arthroplasty, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Patients return to work sooner after unicompartmental knee arthroplasty than after total knee arthroplasty.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2020
    Article
  7. Article
  8. Article
  9. Comparison of patellofemoral outcomes after TKA using two prostheses with different patellofemoral design features.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Arthur J KievitDepartment of Orthopedics, Orthopaedic Research Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Matthias U SchafrothDepartment of Orthopedics, Orthopaedic Research Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Leendert BlankevoortDepartment of Orthopedics, Orthopaedic Research Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Inger N SiereveltDepartment of Orthopedics, Slotervaart Hospital, Amsterdam, the Netherlands.
C Niek van DijkDepartment of Orthopedics, Orthopaedic Research Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Rutger C I van GeenenDepartment of Orthopedics, Amphia Hospital, Breda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A cross-sectional study in two hospitals was performed on 807 patients with a primary Vanguard (Biomet) total knee Arthroplasty (TKA). The research questions addressed were (1) what are the two- and six year survival rates of the Vanguard, (2) what are the clinical outcome scores, (3) what are the findings at revision and (4) what are predictors for revision? The mean age at time of surgery was 67.0 (SD 10.0). The mean follow-up was 3.6 years (95% CI 3.56-3.73). At two years the survival was 97.2% for all-reasons (767 patients remaining) and 99%, for prosthesis-related-reasons (777 remaining). At six years this was 96.5% (40 remaining) and 98.6% (41 remaining). The mean clinical results (84% response on KOOS, Oxford and NRS) were good. A previous osteotomy was a risk factor for revision (hazard ratio 5.1, P=0.001). This early experience with the Vanguard shows a good survival with no adverse outcomes related to the implant and therefore further use of the implant is justified.

Indexed as

Knee ProsthesisAgedArthroplasty, Replacement, KneeCross-Sectional StudiesFemaleFollow-Up StudiesHumansKnee JointMaleMiddle AgedOsteoarthritis, KneeProsthesis FailureReoperationRetrospective StudiesRisk FactorsKaplan–Meier survivalrevision ratesrisk factorstotal knee arthroplastyVanguard

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.